Treatment of psoriasis with topical NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis

Anthony Ormerod, P Copeland, S A Shah

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)


A double blind left, right comparative study was carried out in 17 psoriatic subjects to examine the influence of a topically applied inhibitor of nitric oxide (NO) synthesis on the pathogenic events of psoriasis. The inhibitor NG-monomethyl-L-arginine (L-NMMA) in aqueous cream BP was applied to one plaque while aqueous cream BP alone served as control. Compared with the control, the L-NMMA-treated side showed significant (77%) inhibition of NO production and a reduction in blood flow, confirming its bioavailability. L-NMMA significantly reduced staining for endothelial cells and intercellular adhesion molecule 1, while CD1a-positive Langerhans cells and CD8-positive suppressor cytotoxic T cells increased. CD4-positive lymphocytes and epidermal proliferation, as indicated by Ki-67 staining, were unaffected by this degree of inhibition of NO synthesis, and correspondingly significant clinical improvement was not found.
Original languageEnglish
Pages (from-to)985-990
Number of pages6
JournalBritish Journal of Dermatology
Issue number5
Publication statusPublished - 1 May 2000


  • Adult
  • Aged
  • Biological Availability
  • CD4-Positive T-Lymphocytes
  • Cell Division
  • Double-Blind Method
  • Endothelium
  • Enzyme Inhibitors
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nitric Oxide Synthase
  • Psoriasis
  • Regional Blood Flow
  • Treatment Outcome
  • omega-N-Methylarginine


Dive into the research topics of 'Treatment of psoriasis with topical NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis'. Together they form a unique fingerprint.

Cite this